212 related articles for article (PubMed ID: 34944438)
1. Exploring the Value of
Barma N; Stone TC; Carmona Echeverria LM; Heavey S
Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944438
[TBL] [Abstract][Full Text] [Related]
2. BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.
Alpsoy A; Utturkar SM; Carter BC; Dhiman A; Torregrosa-Allen SE; Currie MP; Elzey BD; Dykhuizen EC
Cancer Res; 2021 Feb; 81(4):820-833. PubMed ID: 33355184
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract][Full Text] [Related]
4. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway.
Fang D; Wang MR; Guan JL; Han YY; Sheng JQ; Tian DA; Li PY
Exp Cell Res; 2021 Sep; 406(2):112727. PubMed ID: 34370992
[TBL] [Abstract][Full Text] [Related]
5. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.
Tse BWC; Volpert M; Ratther E; Stylianou N; Nouri M; McGowan K; Lehman ML; McPherson SJ; Roshan-Moniri M; Butler MS; Caradec J; Gregory-Evans CY; McGovern J; Das R; Takhar M; Erho N; Alshalafa M; Davicioni E; Schaeffer EM; Jenkins RB; Ross AE; Karnes RJ; Den RB; Fazli L; Gregory PA; Gleave ME; Williams ED; Rennie PS; Buttyan R; Gunter JH; Selth LA; Russell PJ; Nelson CC; Hollier BG
Oncogene; 2017 Jun; 36(24):3417-3427. PubMed ID: 28092670
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
7. Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
Barquilha CN; Santos NJ; Monção CCD; Barbosa IC; Lima FO; Justulin LA; Pértega-Gomes N; Felisbino SL
Oxid Med Cell Longev; 2020; 2020():2148562. PubMed ID: 32411320
[TBL] [Abstract][Full Text] [Related]
8. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
9. Independence of HIF1a and androgen signaling pathways in prostate cancer.
Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
[TBL] [Abstract][Full Text] [Related]
11. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
Krämer KF; Moreno N; Frühwald MC; Kerl K
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
[TBL] [Abstract][Full Text] [Related]
12. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
13. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran C; Ouk S; Clegg NJ; Chen Y; Watson PA; Arora V; Wongvipat J; Smith-Jones PM; Yoo D; Kwon A; Wasielewska T; Welsbie D; Chen CD; Higano CS; Beer TM; Hung DT; Scher HI; Jung ME; Sawyers CL
Science; 2009 May; 324(5928):787-90. PubMed ID: 19359544
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
15. miRNA as Regulators of Prostate Carcinogenesis and Endocrine and Chemoresistance.
Culig Z
Curr Cancer Drug Targets; 2021; 21(4):283-288. PubMed ID: 33423646
[TBL] [Abstract][Full Text] [Related]
16. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
Weisberg E; Chowdhury B; Meng C; Case AE; Ni W; Garg S; Sattler M; Azab AK; Sun J; Muz B; Sanchez D; Toure A; Stone RM; Galinsky I; Winer E; Gleim S; Gkountela S; Kedves A; Harrington E; Abrams T; Zoller T; Vaupel A; Manley P; Faller M; Chung B; Chen X; Busenhart P; Stephan C; Calkins K; Bonenfant D; Thoma CR; Forrester W; Griffin JD
Blood Cancer J; 2022 Jul; 12(7):110. PubMed ID: 35853853
[TBL] [Abstract][Full Text] [Related]
17. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
[TBL] [Abstract][Full Text] [Related]
18. BET inhibitor suppresses melanoma progression
Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
[No Abstract] [Full Text] [Related]
19. DNA Damage Repair Deficiency in Prostate Cancer.
Burdak-Rothkamm S; Mansour WY; Rothkamm K
Trends Cancer; 2020 Nov; 6(11):974-984. PubMed ID: 32517958
[TBL] [Abstract][Full Text] [Related]
20. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]